By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves...

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a...

By Karen Roman CareDx, Inc. (Nasdaq: CDNA) said it completed the acquisition of Naveris, which includes its leading product, NavDx, a blood-based test for viral-mediated cancer detection including human papillomavirus, and associated head and neck and anal cancers. NavDx is...

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation. “Today’s news underscores our commitment to...

By Karen Roman SkylineDx said the FDA granted Breakthrough Device Designation to Merlin CP-GEP, the company’s gene expression profile test for risk assessment and clinical decision-making in patients with early-stage cutaneous melanoma. The Merlin CP-GEP is the first and only...

By Karen Roman Imviva Biotech said it has FDA authorization for its Investigational Device Exemption application to use Adaptive Biotechnologies’ clonoSEQ assay in the TENACITY-01 trial to treat leukemia/lymphoma and minimal residual disease. This authorization enables the company to use...

  Tech Edge hosted a fireside chat on June 9 at Pax8 Beyond 2026 in Salt Lake City with Rob Belgrave, Chief Business Officer at Pax8, and Steve Stone, Chief Customer Officer at SentinelOne, Inc. (NYSE: S). The in-person interview was joined...

Watch Video Highlights Below, or Click HERE:  Tech Edge hosted a fireside chat on June 8 at Pax8 Beyond 2026 in Salt Lake City with Renee McCloden, Global Senior Director of Vendor Strategy and Programs at Pax8, and Tim Barton-Wines, Chief...

Watch Video Highlights Below, or Click HERE:  Tech Edge hosted a fireside chat on June 9 at Pax8 Beyond 2026 in Salt Lake City with Ryan Walsh, co-founder, Chief Strategy Officer and Channel Chief at Pax8, and Nyssa Waters, co-founder and...

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head, where he directed the commercial strategy for...